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A b s t r a c t
Background: Technological developments in the embolic protection device (EPD) and stent designs contribute significantly to 
the progress in endovascular management of carotid artery stenosis.
Aim: To evaluate the safety and efficacy of carotid artery stenting (CAS) using a new generation self-expanding nitinol stent, 
Vascuflex SEC, with different types of embolic protection.
Material and methods: Carotid artery stenting with Vascuflex SEC was performed in 50 consecutive patients (age 66.4 ±7.8 years,
men 66%, symptomatic 40%) referred for the procedure after independent neurological consultation. Embolic protection device type
was selected on the basis of atherosclerotic plaque morphology by duplex ultrasound and CT angiography. In a subset of patients 
(n = 20), we tested the feasibility of using intravascular ultrasound with virtual histology (IVUS-VH) to guide the EPD choice and final
stent post-dilation. Proximal neuroprotection by flow reversal or temporary flow cessation was applied in 23 procedures (46%). Clin-
ical evaluation was performed at discharge and at 30 days. 
Results: Procedural success was 100% and, in all cases, only one stent was implanted per patient/lesion. Direct stenting was per-
formed in 20 patients (40%). Intraprocedural IVUS-VH was feasible and safe. Diameter stenosis was reduced from 84.1 ±7.5% to 9.1
±7.7% (p < 0.001). There were two neurological events: one periprocedural ipsilateral minor stroke and one contralateral major stroke
within 30 days. A closure device was used in 80% of patients and no access site complications occurred.
Conclusions: In an unselected population referred for carotid revascularization, CAS with Vascuflex SEC stents is safe and effec-
tive. Lesion morphology-guided selection of EPD may contribute to the low complication rate. 
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S t r e s z c z e n i e
Wstęp: Zwiększenie bezpieczeństwa i stały rozwój zabiegów stentowania tętnic szyjnych (ang. carotid artery stenting, CAS) z zasto-
sowaniem systemów protekcyjnych (ang. embolic protection device, EPD) jest możliwy dzięki postępowi technologicznemu stoso-
wanych urządzeń.
Cel: Ocena skuteczności i bezpieczeństwa CAS z zastosowaniem nowej generacji samorozprężalnych stentów nitinolowych Vascu-
flex SEC.
Materiał i metody: Od stycznia do końca kwietnia 2010 r. zabiegi CAS z implantacją stentów samorozprężalnych Vascuflex SEC
przeprowadzono u kolejnych 50 chorych (33 mężczyzn i 17 kobiet, średnia wieku 66,4 ±7,8 roku, objawy – 20 osób, tj. 40%). Przed
zabiegiem u wszystkich chorych wykonano badanie ultrasonograficzne oraz angio-TK w celu określenia stopnia i morfologii zwęże-
nia. W podgrupie 20 chorych wykonano ultrasonografię wewnątrznaczyniową (ang. intravascular ultrasound with virtual histology,
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Introduction
In the last decade carotid artery stenting with
temporary cerebral protection devices has become
increasingly adopted in the treatment of patients with
atherosclerotic lesions of brain supplying arteries.
A randomized controlled trial, CREST, published in 2010
demonstrated similar direct and long-term results of
carotid artery stenting (CAS) and carotid endarterectomy
(CEA) [1, 2]. Conditions which determine an optimal result
of a carotid artery stenting procedure include operator
experience and adequate stent and protection device
selection tailored to the patient’s clinical condition,
atherosclerotic plaque morphology and the anatomy of
the carotid artery [3-5]. Continuous progress and reduction
of periprocedural complications are influenced by
progressive modernization of the equipment used and
most importantly by the construction of new types of
protection devices and stents. Self-expanding stents are
routinely used for internal carotid artery stenting (ICA)
except stenting of the stenosed ostium of the common
carotid artery and brachiocephalic trunk where metal stents
mounted on a balloon are used. Self-expanding stents used
for CAS procedures may be divided according to design
into open-cell and closed-cell, each possessing different
construction. Differences in the design and characteristics
of self-expanding stents influence the strategy of the CAS
procedure. Closed-cell or open-cell stents should be
selected during the procedure according to atherosclerotic
plaque morphology, the presence of neurological
symptoms and the anatomy of the treated carotid artery
[3-5]. Based on their own experience, the centres per forming
CAS should be equipped with stents of different design
including hybrid stents. Several large registres suggested
that the use of only one stent type and one protection
device type (usually filter) in all treated patients and lessions
can be associates with a high complication rate. 
It should be noted that the criteria of an acceptable
complication rate (death, stroke, myocardial infarction) for
interventional treatment of carotid artery stenosis with
cut-off values of 6% in symptomatic patients and 3% in
asymptomatic patients are still valid [6]. Therefore each
new device dedicated to carotid artery stenting should be
introduced into practice in centres with extensive
experience in CAS procedures. We present the treatment
results in 50 consecutive patients who underwent internal
carotid artery stenting with different temporary cerebral
protection devices and a new generation self-expanding,
open-cell stent – Vascuflex SEC. 
Material and methods
Between January and April 2010 a consecutive group
of 50 patients underwent carotid artery stenting with
different protection devices according to the “Tailored CAS”
algorithm [4] with implantation of a new generation self-
expanding stent, Vascuflex SEC. Prior to the procedure all
patients had ultrasound Doppler of the carotid arteries and
angio-CT of the aortic arch and brain supplying arteries.
Duplex examination supplied by colour Doppler study
initially estimates the degree of artery stenosis and
characterizes atherosclerotic plaque morphology. Angio-
tomography helps in pre-procedural assessment of the
type of aortic arch and in detection of potential anomalies
of brain supplying arteries as well as in quantitative
assessment of stenosis morphology (from adipose through
fibrotic to highly calcified). Both of those non-invasive
studies help in initial planning of the carotid artery stenting
procedure. Qualification for the procedure included
symptomatic patients with > 50% stenosis or asymp -
tomatic patients with ≥ 80% stenosis. All patients were
qualified for the procedure by an independent neurologist
and underwent neurological assessment by the same
neurologist directly after CAS, at discharge and at 30 days
after the procedure. All patients received dual antiplatelet
therapy (aspirin 75 mg/day + clopidogrel 75 mg/day) once
daily for at least 3 days before and after the procedure.
Postprocedural antiplatelet therapy included clopidogrel
for three months and lifelong aspirin. 
A selective coronary angiography was performed in all
patients before the carotid artery stenting procedure to
determine the risk of periprocedural complications. In cases
of severe coronary artery disease patients were qualified
for percutaneous coronary intervention (PCI) or coronary
artery bypass grafting (CABG) at later term. All hypotensive,
diuretic and anti-arrhythmic drugs were withheld on the
day of the procedure and all patients received 500 ml of
IVUS-VH) w celu wstępnej selekcji EPD i oceny postdylatacji po CAS. Zabiegi CAS wykonano u wszystkich chorych z zastosowaniem 
EPD (protekcja proksymalna u 23 chorych – 46%). Chorych poddano ocenie bezpośrednio po zabiegu, w dniu wypisu i po 30 dniach.
U 40 osób (80%) po zabiegu zastosowano urządzenia zamykające tętnicę udową w miejscu wkłucia.
Wyniki: Uzyskano 100-procentową skuteczność zabiegów; u wszystkich chorych implantowano jeden stent. Stwierdzono istot-
ne zmniejszenie stopnia zwężenia tętnicy szyjnej z 84,1 ±7,5% do 9,1 ±7,7%, p < 0,001. Badanie IVUS-VH wykonano bez powikłań.
W trakcie obserwacji szpitalnej i 30-dniowej stwierdzono 2 (4%) incydenty neurologiczne (1 mały udar i 1 konralateralny duży udar).
Nie odnotowano istotnych powikłań miejscowych w analizowanej grupie chorych. 
Wnioski: Zabiegi stentowania tętnic szyjnych z zastosowaniem nitinolowych stentów Vascuflex SEC są procedurą bezpieczną.
Liczba powikłań okołozabiegowych i w 30-dniowej obserwacji nie przekracza wyznaczonych zaleceniami wartości. Na dobre wyniki
stosowanych stentów może mieć wpływ odpowiedni dobór różnych czasowych urządzeń protekcyjnych mózgu.
Słowa kluczowe: zwężenie tętnic szyjnych, angioplastyka tętnic szyjnych, samorozprężalne stenty otwartokomórkowe.
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isotonic saline before the procedure. In all patients carotid
artery stenting was performed with the use of cerebral
protection devices. A subgroup of 20 patients was assessed
for the feasibility of intraprocedural use of intravascular
ultrasound with virtual histology (IVUS-VH) to optimize the
selection of neuroprotective device and stent post-dilation.
A proximal protection device (MoMa/GNPS system) was
used in all symptomatic patients with high risk stenosis
(critical, tortuous, long or ulcerated lesion with the
presence of thrombus). The type and number of protection
devices used in the presented group are shown in table 1. 
All patients received a nitinol self-expanding open-cell
stent – Vascuflex SEC. 
An example of a procedure in a symptomatic, high-risk
patient where a proximal cerebral protection device and
Vascuflex SEC stent were used is presented in figure 1.
During the procedure patients received unfractionated
heparin to maintain activated clotting time (ACT) of 
250-300 s. All patients, except those with an implanted
pacemaker, received 0.5-1.0 mg of atropine before stent
implantation. Most patients underwent direct stent
implantation. Post-dilation was performed in all patients to
maximally optimise the result of the procedure, with residual
Proximal – NPD 23 (46%)
Mo.Ma 8 F 16 (32%)
Gore NPS 7 (14%)
Distal – EPD 27 (54%)
FilterWire EZ 13 (26%)
Emboshield Pro/NAV 10 (20%)
Spider FX 4 (8%)
Table 1. Devices for temporary cerebral protection
(embolic protection device, EPD) used in the stu -
dy cohort
Tabela 1. Czasowe urządzenia protekcyjne mózgu
(EPD) stosowane w badaniu
A B C D E
Fig. 1. RICA-CAS with Vasculfex SEC implantation under proximal protection with Mo.Ma 8 F system. A – angio-
graphically critical, long lesion in a clinically symptomatic patient (arrow). B – RICA flow cessation by inflating
the low-pressure ECA and CCA Mo.Ma system balloons (arrows). C – optimal aposition of the Vascuflex SEC 7.0 ×
× 40 mm carotid stent edges (arrows). D – stent post-dilatation with Viatrac 5.0 × 20 mm balloon (2 × 12 atm/20 s,
arrow). E – optimal angiographic result of the procedure
Ryc. 1. Zabieg stenowania tętnicy szyjnej wewnętrznej prawej z implantacją stentu Vascuflex SEC przy zastosowaniu
systemu neuroprotekcji proksymalnej Mo.Ma 8 F. A – krytyczne długoodcinkowe, klinicznie objawowe zwężenie
tętnicy szyjnej wewnętrznej prawej w odcinku proksymalnym (strzałka). B – zahamowanie przepływu w tętnicy
szyjnej wspólnej i zewnętrznej prawej niskociśnieniowymi balonami systemu Mo.Ma (strzałki). C – optymalna
apozycja proksymalnego i dystalnego odcinka stentu Vascuflex SEC 7,0 × 40 mm do ściany naczynia (strzałki). 
D – postdylatacja stentu cewnikiem balonowym Viatrac 5,0 × 20 mm inflacją 2 × 12 atm/20 s (strzałka). E – opty-
malny efekt angiograficzny zabiegu
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stenosis not exceeding 30%. All patients under went pre-
and postprocedural intracranial angiography to exclude
periprocedural embolic complications. In most patients (after
initial femoral artery angiography) the arterial puncture site
was closed using a closure device to allow faster patient
mobilization after the procedure. An ultrasound examination
was performed before discharge and 30 days after CAS to
check the implanted stent. A neurological consultation was
done to assess any neurological incidents which occurred
during 30 days of follow-up.
Results
Between January and April 2010 a group of 50 conse -
cutive patients with critical internal carotid artery stenosis
and mean age of 66.4 ±7.9 years (33 men and 17 women)
was included in the registry. Demographic data and clinical
characteristics of the studied group are presented in table 2.
Twenty patients (40%) had a history of neurological
incidents during the 6 months preceding CAS. Eight
patients (16%) had an occlusion of the contralateral carotid
artery. Routinely performed coronary angiography showed
the presence of significant coronary artery disease in 
33 (66%) patients (tab. 2). 
Mean stenosis was 84 ±7.5% (70-99%) before the
procedure and 9.1 ±7.7% (0-30%) after the procedure 
(p < 0.001). Six patients (12%) had pre-procedural stenosis
of 95-99%. Intraprocedural assessment of stenosis by
means of IVUS-VH was feasible and safe. Proximal
protection devices were used in a high percentage of
patients (46%). Direct stenting technique was performed
in 20 patients (40%). Procedural success of stent
implantation was 100% and, in all cases, only one stent
was implanted per patient/lesion. In all patients stent
implantation was followed by stent post-dilation to obtain
residual stenosis not exceeding 30%. An additional stent
post-dilation with a 0.5 mm larger balloon was performed
in 1 patient (1/20, 5%) after assessment of in-stent minimal
lumen area by means of intravascular ultrasound. 
There were no cases of major stroke, myocardial
infarction or death during CAS, directly after the procedure
or throughout the hospitalization period. A minor stroke
with complete resolution of symptoms during hospi -
talization was diagnosed in one patient by the consulting
neurologist. There were no signs of intracranial bleeding
or acute ischaemic foci in the brain on the CT scan in that
patient. A transient ischaemic attack (TIA) occurred in three
patients during the procedure. Two of those patients had
a contralateral carotid artery occlusion and one had
a critical contralateral stenosis. All patients completely
recovered before transportation from the cath lab to the
ward. There were no cases of death, myocardial infarction
or minor stroke between discharge and day 30 of the
follow-up. One female patient suffered from major
contralateral stroke 5 days after discharge and 7 days after
CAS. The stroke occurred in the hemisphere supplied by
a chronically occluded carotid artery – contralateral to the
stented artery. Ultrasound assessment of the implanted
stent showed its good patency and apposition. In-hospital
and 30-day complications in symptomatic and asymp -
tomatic patients are presented in table 3. In 40 patients
Number of patients 50 (100%)
Age in years (range) 66.4 ±7.9 (48-78)
> 75 years of age 8 (16%)
Men 33 (66%)
Neurological symptoms present 20 (40%)
Previous ipsilateral stroke 14 (28%)
Previous ipsilateral TIA 9 (18%)
Previous amaurosis fugax 4 (8%)
Cigarette smoking (active or in the past) 23 (46%)
Hypertension 45 (90%)
Diabetes 7 (14%)
Hypercholesterolaemia 47 (94%)
Peripheral arterial disease 5 (10%)
Angiographically proven coronary artery disease 33 (66%)
Previous myocardial infarction 20 (40%)
Bilateral ICA stenosis 15 (30%)
Contralateral ICA occlusion 8 (16%)
Table 2. Demographic and clinical characteristics
of the studied group
Tabela 2. Demograficzna i kliniczna charakterysty-
ka chorych
Complications Patients Symptomatic Asymptomatic Value 
(n = 50) (n = 20) (n = 30) of p
Death 0 (0%)
Major stroke 1 (2%) 1 (5%) 0 (0%) NS
Minor stroke 1 (2%) 0 (0%) 1 (3%) NS
Any stroke 2 (4%)
Myocardial 0 (0%)
infarction
Death/major 1 (2%) 1 (5%) 0 (0%) NS
stroke/myocardial 
infarction
Death/any stroke/ 2 (4%) 1 (5%) 1 (3%) NS
myocardial 
infarction
TIA 3 (6%) 1 (5%) 2 (6%) NS
Hyperperfusion 0 (0%)
syndrome
Artery dissection 0 (0%)
Table 3. Periprocedural and 30-day complications
of CAS
Tabela 3. Okołozabiegowe i 30-dniowe powikłania
zabiegów CAS
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(80%) the femoral artery was closed using the Angioseal
6 or 8 F closure device. Complications at the puncture site
in the form of pseudoaneurysm were observed in only one
patient and were successfully treated with local thrombin
admi nistration. 
Statistical analysis was performed by means of non-
parametric Wilcoxon test.
Discussion
The growing number of CAS procedures is a result of
new guidelines based on the results of recent randomized
trials comparing endovascular and surgical treatment
indicated high efficacy of percutaneous treatment of
atherosclerotic changes in the brain supplying arteries [8,
9]. Several years of experience in carotid artery stenting
and the growing significance of proximal devices used for
CAS caused a marked reduction of the periprocedural
complication rate and a shift from periprocedural towards
postprocedural complications [9].
It is estimated that 2/3 of all complications occur after
the CAS procedure and are caused by migration of embolic
material through the stent cells. Therefore adequate stent
apposition to the atherosclerotic plaque and artery wall is
crucial and can be best obtained with the use of open-cell
stents. A second key element is to avoid embolic material
migration through stent cells in the postprocedural period.
In this situation closed-cell stents have a marked
advantage. The size of self-expandable stent cells varies
greatly and ranges from 1.08 mm2 for the Carotid Wallstent
to 11.48 mm2 for the Acculink stent. This characteristic can
have an influence on the size of embolic material and
therefore clinical consequences caused by migration of
atherosclerotic plaque parts to the cerebral circulation.
Bosiers et al. [10] demonstrated in their analysis that the
use of open-cell stents is related to higher risk of
complications in comparison to closed-cell stents. Our
studies did not demonstrate differences in direct and long-
term results of CAS for both types of stents if cerebral
protection devices and, preferably, closed-cell stents are
used in symptomatic patients and in patients with high
risk lesions [3].
It should be noted that open-cell stents better adapt
to tortuous segments of carotid arteries and therefore they
have a well-established position as first choice stents in
patients with tortuous and calcified carotid arteries treated
with the endovascular method [11]. In a 2-year observation
period Muller-Hulsbeck et al. found no difference in terms
of complications between open- and closed-cell stents
implanted in the carotid arteries [12].
In our study using open-cell stents in consecutive
patients we registered a very low complication rate of 4%.
It should be noted that minor stroke was diagnosed in
a patient with partial aphasia which persisted over 24 h
following the procedure and resolved without sequelae 
5 days after the procedure. A major stroke in the right
hemisphere (the third one in 10 years occurring in the
presence of ipsilateral carotid artery occlusion) can hardly
be related to left internal carotid artery stenting. It should
be noted that such good results obtained in a group of
40% of symptomatic patients could have been influenced
by the selection of protection devices according to the
“Tailored CAS” algorithm. It should also be noted that in
23 patients (46%) a proximal cerebral protection was used
(MoMa and GNPS system – tab. 1).
Vascuflex SEC stents have a relatively small area of the
cells of 9.3 mm2, which also could have influenced the
favourable results of the procedure in the analysed group.
Nowadays it is hard to perform carotid artery stenting
solely with the use of closed-cell stents. The properties of
nitinol self-expandable stents are sometimes crucial for
a correctly conducted CAS procedure. However, the selection
of stent used for carotid artery stenting should be best
based on the morphology of the atherosclerotic plaque and
on the anatomy of the stenosed artery [3, 4, 12].
Conclusions
Carotid artery stenting with nitinol open-cell Vascuflex
SEC stents is a safe procedure. The rate of periprocedural
and 30-day complications does not exceed the values
accepted by the guidelines. The favourable results obtained
using the described stents may have been influenced by
the selection of protection devices according to the
“tailored CAS” algorithm.
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